Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kuo, Yi Jie ^a,b   Tsuang, Fon Yih ^c   Sun, Jui Sheng ^c,d   Lin, Chi Hung ^b   Chen, Chia Hsien ^b   Li, Jia Ying ^e   Huang, Yi Chian ^b   Chen, Wei Yu ^e   Yeh, Chin Bin ^f   Shyu, Jia Fwu ^e,f  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CASPASE 3; CASPASE 8; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROTEIN BCL 2; PROTEIN MCL 1; SALCATONIN; SINTERED DICALCIUM PYROPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE VOLUME; CELL ASSAY; CELL COUNT; CELL ISOLATION; CELL SIZE; CELL SURVIVAL; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; INTRACELLULAR SIGNALING; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RABBIT; RAT; TRABECULAR BONE; TRABECULAR NUMBER; TRABECULAR THICKNESS;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM PYROPHOSPHATE; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; LUMBAR VERTEBRAE; MAP KINASE SIGNALING SYSTEM; OSTEOCLASTS; OSTEOPOROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS; VERTEBRATA;

EID: 84863713400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040272     Document Type: Article

References (42)

1. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. (1999) Molecular mechanisms of action of bisphosphonates. Bone 24: 73S-79S.
2. Drake MT, Clarke BL, Khosla S, (2008) Bisphosphonates: mechanism of action and role in clincal practice. Mayo Clin Proc 83: 1032-1045.
3. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J, (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34-41.
4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589.
5. Karsdal MA, Henriksen K, Arnold M, Christiansen C, (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22: 137-144.
6. de Paula FJ, Rosen CJ, (2010) Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling. Horm Metab Res 42: 299-306.
7. Gallagher JC, Sai AJ, (2010) Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 65: 301-307.
8. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, et al. (2006) Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology 147: 4010-4021.
9. Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, et al. (2008) Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 23: 1182-1193.
10. Marzia M, Chiusaroli R, Neff L, Kim NY, Chishti AH, et al. (2006) Calpain is required for normal osteoclast function and is down-regulated by calcitonin. J Biol Chem 281: 9745-9754.
11. Shyu JF, Shih C, Tseng CY, Lin CH, Sun DT, et al. (2007) Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone 40: 1329-1342.
12. Stern PH, (2007) Antiresorptive agents and osteoclast apoptosis. J Cell Biochem 101: 1087-1096.
13. Selander KS, Härkönen PL, Valve E, Mönkkönen J, Hannuniemi R, et al. (1996) Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol 122: 119-129.
14. Kanaoka K, Kobayashi Y, Hashimoto F, Nakashima T, Shibata M, et al. (2000) A common downstream signaling activity of osteoclast survival factors that prevent nitric oxide-promoted osteoclast apoptosis. Endocrinology 141: 2995-3005.
15. Miyazaki T, Neff L, Tanaka S, Horne WC, Baron R, (2003) Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J Cell Biol 160: 709-718.
16. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, et al. (2002) Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110: 1849-1857.
17. Huebner AK, Schinke T, Priemel M, Schilling S, Schilling AF, et al. (2006) Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res 2006 21: 1924-1934.
18. Lin FH, Lin CC, Lu CM, Liu HC, Sun JS, et al. (1995) Mechanical properties and histological evaluation of sintered beta-Ca2P2O7 with Na4P2O7.10H2O addition. Biomaterials 16: 793-802.
19. Sun JS, Tsuang YH, Liao CJ, Liu HC, Hang YS, et al. (1997) The effects of calcium phosphate particles on the growth of osteoblasts. J Biomed Mater Res 37: 324-334.
20. Sun JS, Huang YC, Tsuang YH, Chen LT, Lin FH, (2002) Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats. J Biomed Mater Res59: 246-253.
21. Sun JS, Huang YC, Lin FH, Chen LT, (2003) The effect of sintered dicalcium pyrophosphate on osteoclast metabolism: an ultrastructural study. J Biomed Mater Res A 64: 616-621.
22. Karsdal MA, Henriksen K, Arnold M, Christiansen C, (2008) Calcitonin- A drug of the Past or for the Future? BioDrugs 22: 137-144.
23. Chambers TJ, Athanasou NA, Fuller K, (1984) Effect of parathyroid hormone and calcitonin on the cytoplasmic spreading of isolated osteoclasts. J Endocrinol 102: 281-286.
24. Zaidi M, Chambers TJ, Moonga BS, Oldoni T, Passarella E, et al. (1990) A new approach for calcitonin determination based on target cell responsiveness. J Endocrinol Invest 13: 119-126.
25. Sutherland KA, Rogers HL, Tosh D, Rogers MJ, (2009) RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 11: R58.
26. Tanaka S, Wakeyama H, Akiyama T, Takahashi K, Amano H, et al. (2010) Regulation of osteoclast apoptosis by bcl-2 family protein bim and caspase-3. Adv Exp Med Biol 658: 111-116.
27. Horne WC, Sanjay A, Baron R, (2008) Regulating Bone Resorption: Targeting Integrins, Calcitonin Receptor, and Cathepsin K, in: J.P. Bilezikian, T.J. Martin (Eds.) Principles of Bone Biology 3rd ed., Academic Press, New York, NY, USA, 221-236.
28. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, et al. (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333-342.
29. Allan LA, Morrice N, Brady S, Magee G, Pathak S, et al. (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5: 647-654.
30. Ogawa K, Hori M, Takao R, Sakurada T, (2005) Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 23: 351-358.
31. Ozoran K, Yildirim M, ÖNDER M, Sivas F, Inanir A, (2007) The bone mineral density effects of calcitonin and alendronate combined therapy in patients with rheumatoid arthritis. APLAR J Rheumatol 10: 17-22.
32. Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H, (2009) Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis. Ther Clin Risk Manag 5: 499-505.
33. Martin T, Gooi JH, Sims NA, (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 19: 73-88.
34. Mochizuki K, Inoue T, (2000) Effect of salmon calcitonin on experimental osteoporosis induced by ovariectomy and low-calcium diet in the rat. J Bone Miner Metab 18: 194-207.
35. Davey RA, Morris HA, (2005) The effects of salmon calcitonin-induced hypocalcemia on bone metabolism in ovariectomized rats. J Bone Miner Metab 23: 359-365.
36. Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, et al. (2000) Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biol Pharm Bull 23: 946-951.
37. Huebner AK, Keller J, Catala-Lehnen P, Perkovic S, Streichert T, et al. (2008) The role of calcitonin and alpha-calcitonin gene-related peptide in bone formation. Arch Biochem Biophys 473: 210-217.
38. Sun JS, Tsuang YH, Liao CJ, Liu HC, Hang YS, et al. (1999) The effect of sintered beta-dicalcium pyrophosphate particle size on newborn Wistar rat osteoblasts. Artif Organs 23: 331-338.
39. Penolazzi L, Lampronti I, Borgatti M, Khan MT, Zennaro M, et al. (2008) Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis. BMC Complement Altern Med 8: 59.
40. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, et al. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25: 1468-1486.
41. Hildebrand T, Ruegsegger P, (1997) Quantification of Bone Microarchitecture with the Structure Model Index. Comput Methods Biomech Biomed Engin 1: 15-23.
42. Lin C, Moniz C, Chambers TJ, Chow JWM, (1996) Colitis causes bone loss in rats through suppression of bone formation. Gastroenterol 11: 1263-1271.